San Carlos, CA, United States
San Carlos, CA, United States

Time filter

Source Type

STEVENSON, Md., Feb. 26, 2017 (GLOBE NEWSWIRE) -- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Northern District of California on behalf of purchasers of Natus Medical Incorporated (Nasdaq:BABY) (“Natus” or the “Company”) common stock during the period between October 16, 2015 and April 3, 2016, inclusive (the “Class Period”).  Investors who wish to become proactively involved in the litigation have until March 31, 2017 to seek appointment as lead plaintiff. If you wish to choose counsel to represent you and the Class, you must apply to be appointed lead plaintiff and be selected by the Court.  The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the Class in the action.  The lead plaintiff will be selected from among applicants claiming the largest loss from investment in Natus common stock during the Class Period.  Members of the Class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff.  No class has yet been certified in the above action. The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of the defendants’ failure to disclose during the Class Period that: the government of Venezuela failed to make tens of millions of dollars in prepayments to Natus, which were required to be paid in October 2015; Natus could not effectively enforce its rights under its supply contract and its revenues related to the supply contract were dependent on the outcome of Venezuelan elections; and, Natus could not effectively achieve its guidance. According to the complaint, following a January 11, 2016 announcement that Venezuela had not made expected payments due to a delay, a January 27, 2016 announcement reaffirming a revenue shortfall due to the delay, a February 29, 2016 filing disclosing that the prepayments were due in October 2015, and an April 4, 2016 announcement that the Company still had not received the prepayments and the Company missed its guidance, the value of Natus shares declined significantly. If you have suffered a loss in excess of $100,000 from investment in Natus common stock purchased on or after October 16, 2015 and held through the revelation of negative information during and/or at the end of the Class Period and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, without cost or obligation to you, please visit our website at http://www.browerpiven.com/currentsecuritiescases.html.  You may also request more information by contacting Brower Piven either by email at hoffman@browerpiven.com or by telephone at (410) 415-6616.  Brower Piven also encourages anyone with information regarding the Company’s conduct during the period in question to contact the firm, including whistleblowers, former employees, shareholders and others. Attorneys at Brower Piven have extensive experience in litigating securities and other class action cases and have been advocating for the rights of shareholders since the 1980s.  If you choose to retain counsel, you may retain Brower Piven without financial obligation or cost to you, or you may retain other counsel of your choice.  You need take no action at this time to be a member of the class.


NEW ORLEANS, Feb. 01, 2017 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., reminds investors that they have until March 31, 2017 to file lead plaintiff applications in a securities class action lawsuit against Natus Medical Incorporated (Nasdaq:BABY), if they purchased the Company’s shares between October 16, 2015 and April 3, 2016, inclusive (the “Class Period”).  The action is pending in United States District Court for the Northern District of California.  What You May Do If you purchased shares of Natus and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, call toll-free at 1-877-515-1850 or email KSF Managing Partner Lewis Kahn (lewis.kahn@ksfcounsel.com). If you wish to serve as a lead plaintiff in this class action, you must petition the Court by March 31, 2017. Natus and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws. The alleged false and misleading statements and omissions include, but are not limited to, that: (i) the Venezuelan government had not made tens of millions of dollars in prepayments to Natus under their three-year supply contract ("Supply Contract"); (ii) Natus had no means to effectively enforce the Supply Contract, as Venezuela was the exclusive forum for dispute resolution; (iii) Natus's receipt of revenues under the Supply Contract was contingent on the Venezuelan elections; and (iv) accordingly, Natus was not on track to achieve the increased guidance it provided and such guidance lacked a reasonable basis. KSF, whose partners include the Former Louisiana Attorney General Charles C. Foti, Jr., is a law firm focused on securities, antitrust and consumer class actions, along with merger & acquisition and breach of fiduciary litigation against publicly traded companies on behalf of shareholders. The firm has offices in New York, California and Louisiana. To learn more about KSF, you may visit www.ksfcounsel.com.


NEW YORK, Feb. 20, 2017 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of Natus Medical Incorporated securities (NASDAQ:BABY) from October 16, 2015 through April 3, 2016, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Natus investors under the federal securities laws. To join the Natus class action, go to http://rosenlegal.com/cases-1045.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or kchan@rosenlegal.com for information on the class action. NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. According to the lawsuit, throughout the Class Period Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about Natus’ business, operations, and prospects, including that: (1) the Venezuelan government failed to make tens of millions of dollars in prepayments to Natus, which were required to have been paid beginning in October 2015; (2) Natus had no means to effectively enforce its rights under its supply contract, as Venezuela was the exclusive forum for dispute resolution; (3) Natus’ receipt of revenues pursuant to the supply contract was contingent on the outcome of Venezuelan elections; and (4) as a result, Natus was not on track to achieve the increased guidance provided by Defendants, which lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than March 31, 2017. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://rosenlegal.com/cases-1045.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at pkim@rosenlegal.com or kchan@rosenlegal.com. Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm. Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.


Research and Markets has announced the addition of the "Global Infant Warmers and Incubators Market Analysis & Trends - Product Type (Transport Incubator, Labor and Delivery and Neonatal intensive care unit (NICU)) - Forecast to 2025" report to their offering. The study focuses on market trends, leading players, supply chain trends, technological innovations, key developments, and future strategies. With comprehensive market assessment across the major geographies such as North America, Europe, Asia Pacific, Middle East, Latin America and Rest of the world the report is a valuable asset for the existing players, new entrants and the future investors. Some of the prominent trends that the market is witnessing include improvement of integrated and multifunctional infant care equipment, rise in NICU admissions count, recent technological developments of Infant Warmers and Incubators and growth opportunities/investment opportunities. Based on product type the market is categorized into transport incubator, labor and delivery and neonatal intensive care unit (NICU). Transport incubator is further segmented by external transport incubator and internal transport incubator. labor and delivery is sub divided into labor and delivery warmer and labor and delivery incubator. Neonatal intensive care unit (NICU) is further segmented by NICU convertible warmer/incubator, NICU incubator and NICU warmer. This industry report analyzes the global markets for Infant Warmers and Incubators across all the given segments on global as well as regional levels presented in the research scope. The study provides historical market data for 2013, 2014 revenue estimations are presented for 2015 and forecasts from 2016 till 2025. - The report provides a detailed analysis on current and future market trends to identify the investment opportunities - Market forecasts till 2025, using estimated market values as the base numbers - Key market trends across the business segments, Regions and Countries - Key developments and strategies observed in the market - Market Dynamics such as Drivers, Restraints, Opportunities and other trends - In-depth company profiles of key players and upcoming prominent players - Growth prospects among the emerging nations through 2025 - Market opportunities and recommendations for new investments Key Topics Covered: 1 Market Outline 2 Executive Summary 3 Market Overview 3.1 Current Trends 3.1.1 Improvement of Integrated And Multifunctional Infant Care Equipment 3.1.2 Rise in NICU Admissions Count 3.1.3 Recent Technological Developments of Infant Warmers and Incubators 3.1.4 Growth Opportunities/Investment Opportunities 3.2 Drivers 3.3 Constraints 3.4 Industry Attractiveness 4 Infant Warmers and Incubators Market, By Product Type 4.1 Transport Incubator 4.1.1 Transport Incubator Market Forecast to 2025 (US$ MN) 4.1.1.1 External Transport Incubator 4.1.1.1.1 External Transport Incubator Market Forecast to 2025 (US$ MN) 4.1.1.2 Internal Transport Incubator 4.1.1.2.1 Internal Transport Incubator Market Forecast to 2025 (US$ MN) 4.2 Labor And Delivery 4.2.1 Labor And Delivery Market Forecast to 2025 (US$ MN) 4.2.1.1 Labor And Delivery Warmer 4.2.1.1.1 Labor And Delivery Warmer Market Forecast to 2025 (US$ MN) 4.2.1.2 Labor And Delivery Incubator 4.2.1.2.1 Labor And Delivery Incubator Market Forecast to 2025 (US$ MN) 4.3 Neonatal intensive care unit (NICU) 4.3.1 Neonatal intensive care unit (NICU) Market Forecast to 2025 (US$ MN) 4.3.1.1 NICU Convertible Warmer/Incubator 4.3.1.1.1 NICU Convertible Warmer/Incubator Market Forecast to 2025 (US$ MN) 4.3.1.2 NICU Incubator 4.3.1.2.1 NICU Incubator Market Forecast to 2025 (US$ MN) 4.3.1.3 NICU Warmer 4.3.1.3.1 NICU Warmer Market Forecast to 2025 (US$ MN) 5 Infant Warmers and Incubators Market, By Geography 6 Key Player Activities 6.1 Mergers & Acquisitions 6.2 Partnerships, Joint Venture's, Collaborations and Agreements 6.3 Product Launch & Expansions 6.4 Other Activities 7 Leading Companies 7.1 Natus Medical Incorporated 7.2 Weyer GmbH 7.3 GE Healthcare 7.4 Phoenix Medical Systems 7.5 International Biomedical 7.6 Philips Healthcare 7.7 Dräger Medical 7.8 Datex Ohmeda Ltd 7.9 Smiths Medical 7.10 Fisher & Paykel Healthcare Corp. 7.11 MTTS 7.12 AVI Healthcare 7.13 Nonin Medical 7.14 Natus Medical 7.15 Ibis Medical For more information about this report visit http://www.researchandmarkets.com/research/5kh6bc/global_infant


News Article | February 28, 2017
Site: globenewswire.com

PLEASANTON, Calif., Feb. 28, 2017 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ:BABY) today announced that Jonathan Kennedy, Executive Vice-President and Chief Financial Officer will present at the Raymond James 38th Annual Institutional Investors Conference in Orlando, Florida. Mr. Kennedy is scheduled to present on Monday, March 6th at 7:30 a.m. Eastern Time (4:30 a.m. PT). Investors may listen to a live webcast and view a copy of the slide presentation online via the “Investors” section of the Company’s web site at http://investor.natus.com. The recorded webcast will be accessible online for at least 30 days. Natus is a leading provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders. Additional information about Natus Medical can be found at www.natus.com.


NEW YORK--(BUSINESS WIRE)--The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Northern District of California on behalf of investors who purchased Natus Medical Incorporated (NASDAQ:BABY) securities between October 16, 2015 and April 3, 2016. Click here to learn about the case: http://www.wongesq.com/pslra/natus-medical-incorporated. There is no cost or obligation to you. According to the complaint, throughout the Class Period Defendants made materially false and/or misleading statements and/or failed to disclose material adverse facts, including that: (1) the Venezuelan government failed to make tens of millions of dollars in prepayments to Natus, which were required to have been paid beginning in October 2015; (2) Natus had no means to effectively enforce its rights under its supply contract, as Venezuela was the exclusive forum for dispute resolution; (3) Natus’ receipt of revenues pursuant to the supply contract was contingent on the outcome of Venezuelan elections; and (4) as a result, Natus was not on track to achieve the increased guidance provided by Defendants, which lacked a reasonable basis. If you suffered a loss in Natus you have until March 31, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email vw@wongesq.com, by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/natus-medical-incorporated. Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.


A method and device for automatically assessing loss of hearing sensitivity and compression (recruitment) with user defined frequency resolution by means of extrapolated DPOAE I/O functions and ABRs as well as for automatically fitting hearing aids without any cooperation of the subject tested using a device having a display screen attached to a handheld device generating and collecting otoacoustic emission signals and brain stem response signals into a programmed with a clinical audiogram with fitting parameters for hearing aids calculated on the basis of assessed hearing threshold and compression and identifying the type of hearing required for the individual.


Patent
Natus Medical | Date: 2012-07-09

The described embodiments relate generally to methods, systems and devices for sleep stage determination using frontal electrodes. Certain embodiments relate to a system for sleep stage determination comprising a sensing unit and a processing unit. The sensing unit is positioned over a forehead area of a patient and has first, second and third electrodes for positioning at locations on or adjacent the forehead area for detecting electrical potentials of a human head. The processing unit is coupled to the sensing unit for receiving biological signals corresponding to the detected electrical potentials and processing the biological signals to determine a sleep stage of the patient. The processing of the biological signals is based on a plurality of rules.


Patent
Natus Medical | Date: 2014-10-22

A method and apparatus for determining the impedance of the plurality of channels comprising a plurality of channels having a plurality of first channels and a plurality of second channels, at least one reference channel, a signal generator electrically connected to the plurality of channels, a reference signal generator connected to the reference channel, at least one amplifier connected to each of the plurality of channels and the reference channel and at least one filter connected to an output of the at least one amplifier to filter the output signal from the at least one amplifier. The signal generator is configured to provide a plurality of input signals to the plurality of channels. The reference signal generator provides an input signal to the reference channel.


NEW YORK, Feb. 14, 2017 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Natus Medical Incorporated (“Natus”) (NASDAQ:BABY) between October 16, 2015 and April 3, 2016. You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the Northern District of California. To get more information go to: or contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you. The complaint alleges that throughout the Class Period Defendants made materially false and/or misleading statements and/or failed to disclose material adverse facts, including that: (1) the Venezuelan government failed to make tens of millions of dollars in prepayments to Natus, which were required to have been paid beginning in October 2015; (2) Natus had no means to effectively enforce its rights under its supply contract, as Venezuela was the exclusive forum for dispute resolution; (3) Natus’ receipt of revenues pursuant to the supply contract was contingent on the outcome of Venezuelan elections; and (4) as a result, Natus was not on track to achieve the increased guidance provided by Defendants, which lacked a reasonable basis. If you suffered a loss in Natus you have until March 31, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

Loading Natus Medical collaborators
Loading Natus Medical collaborators